ArticleFrontiers in veterinary science2026
The preventive effect of chlorogenic acid on cisplatin-induced acute kidney injury in mice.
Article in Frontiers in veterinary science, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
- Erratum issued
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Acute kidney injury (AKI) is a common clinical syndrome. Chlorogenic acid (CGA) is a natural polyphenol with antioxidant and anti-inflammatory properties. In this study, 60 male Kunming mice were randomly assigned to 6 groups: Control (CON), Cisplatin (CIS), CGA, CIS + CGA, CIS + furosemide (FUR), and FUR. Kidney injury markers, inflammatory indicators, antioxidant enzyme activities, oxidative products, antioxidant proteins, and kidney morphology were assessed using ELISA, histology, and Western blot. Preventive CGA supplementation significantly reduced levels of creatinine (Cr), BUN, KIM-1, and MDA, while restoring the enzymatic activities of SOD, GSH-Px, CAT, and T-AOC. CGA also increased the expression of Nrf2 and GCLC proteins and decreased the expression of Keap1 protein. Levels of IL-1β, IL-2, and IL-6 were reduced, while IL-10 levels were elevated. These results indicate that preventive CGA supplementation effectively mitigates CIS-induced AKI by enhancing antioxidant capacity, attenuating inflammatory responses, and ameliorating kidney structural damage.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.